Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses

H. Tsuchida, S. Takahashi, E. Nosaka, O. Mukaiyama, K. Morimoto, M. Yamashita (Tokyo, Japan)

Source: Annual Congress 2006 - Novel treatments for asthma
Session: Novel treatments for asthma
Session type: Oral Presentation
Number: 750
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Tsuchida, S. Takahashi, E. Nosaka, O. Mukaiyama, K. Morimoto, M. Yamashita (Tokyo, Japan). Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses. Eur Respir J 2006; 28: Suppl. 50, 750

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist
Source: Eur Respir J 2001; 18: Suppl. 33, 264s
Year: 2001

The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A (NKA)-induced bronchoconstriction in patients with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 415s
Year: 2003

Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 219s
Year: 2004

Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012

The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan
Source: Annual Congress 2010 - Airway smooth muscle cells
Year: 2010

In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407
Source: Eur Respir J 2007; 30: Suppl. 51, 26s
Year: 2007

CS-003, a novel triple neurokinin receptor antagonist, inhibits symptoms of respiratory diseases models in guinea pigs
Source: Eur Respir J 2006; 28: Suppl. 50, 664s
Year: 2006

Evaluation of a selective 5-hydroxytryptamine 2B receptor antagonist designed to alter the fibrotic process
Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents
Year: 2017




Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012

Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients
Source: Eur Respir J 2004; 23: 76-81
Year: 2004



Inhibition of cough reflex by D2 receptor agonism with Viozan™ (AR-C68397AA)
Source: Eur Respir J 2001; 18: Suppl. 33, 32s
Year: 2001

In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist
Source: Eur Respir J 2007; 30: Suppl. 51, 25s
Year: 2007

Modulatory role of tachykinin NK1 receptor in cholinergic contraction of mouse trachea
Source: Eur Respir J 2003; 21: 3-10
Year: 2003



Modulation of cortical and respiratory activity by 5-HT2 receptor agonist in the rat
Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep
Year: 2008

A new ultra-potent vanilloid receptor 1 (VR1) antagonist abates capsaicin and citric acid induced cough
Source: Eur Respir J 2002; 20: Suppl. 38, 190s
Year: 2002

The novel dual D2 dopamine receptor, β2-adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model
Source: Eur Respir J 2001; 18: Suppl. 33, 406s
Year: 2001

Effects of a newly developed dual CysLT1 and CysLT2 receptor antagonist, ONO-RS-531, on antigen- and leukotriene D4-induced contractions of isolated human bronchi
Source: Eur Respir J 2005; 26: Suppl. 49, 214s
Year: 2005

Adenosine but not the A2A adenosine receptor agonist, CGS 21680 attenuates the endothelial cell barrier disruption induced by lipopolysaccharide
Source: Annual Congress 2011 - Anti-inflammatory strategies in acute lung injury
Year: 2011


The antitussive effects of alpha7 (a7) nicotinic receptor agonists
Source: International Congress 2017 – Novel studies on bronchodilators and cough
Year: 2017